CA
GPCR icon

Clearstead Advisors’s Structure Therapeutics GPCR Stock Holding History

Clearstead Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
+7,826
New +$346K ﹤0.01% 813
2025
Q2 		– Sell
-67
Closed -$1.16K – 2794
2025
Q1 		$1.16K Hold
67
– – ﹤0.01% 1975
2024
Q4 		$1.82K Hold
67
– – ﹤0.01% 1856
2024
Q3 		$2.94K Hold
67
– – ﹤0.01% 1787
2024
Q2 		$2.63K Buy
67
+8
+14% +$328 ﹤0.01% 1786
2024
Q1 		$2.12K Hold
59
– – ﹤0.01% 1303
2023
Q4 		$2.4K Buy
59
+24
+69% +$1.38K ﹤0.01% 1260
2023
Q3 		$1.76K Buy
+35
New +$1.13K ﹤0.01% 1266

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Clearstead Advisors's GPCR Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 7,826 shares worth $420K. The stake represents ﹤0.01% of the portfolio and ranks #813 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in GPCR as recently as Q1 2025.

Clearstead Advisors first reported a position in GPCR in Q3 2023 and has held it in 8 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Clearstead Advisors held 7,826 shares of Structure Therapeutics worth $420K as of Q2 2026.
  • Structure Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #813 holding.
  • Clearstead Advisors first reported a position in Structure Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.